Cargando…
A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults
BACKGROUND: We conducted a phase I, randomized, double-blind, placebo-controlled trial to assess the safety and immunogenicity of escalating doses of two recombinant replication defective adenovirus serotype 35 (Ad35) vectors containing gag, reverse transcriptase, integrase and nef (Ad35-GRIN) and e...
Autores principales: | Keefer, Michael C., Gilmour, Jill, Hayes, Peter, Gill, Dilbinder, Kopycinski, Jakub, Cheeseman, Hannah, Cashin-Cox, Michelle, Naarding, Marloes, Clark, Lorna, Fernandez, Natalia, Bunce, Catherine A., Hay, Christine M., Welsh, Sabrina, Komaroff, Wendy, Hachaambwa, Lottie, Tarragona-Fiol, Tony, Sayeed, Eddy, Zachariah, Devika, Ackland, James, Loughran, Kelley, Barin, Burc, Cormier, Emmanuel, Cox, Josephine H., Fast, Patricia, Excler, Jean-Louis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411704/ https://www.ncbi.nlm.nih.gov/pubmed/22870265 http://dx.doi.org/10.1371/journal.pone.0041936 |
Ejemplares similares
-
Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults
por: Kopycinski, Jakub, et al.
Publicado: (2014) -
Vaccine responses to conserved regions of the HIV-1 proteome are associated with an increased capacity to inhibit multiple virus isolates ex vivo
por: Ashraf, A, et al.
Publicado: (2012) -
Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine
por: Vasan, Sandhya, et al.
Publicado: (2010) -
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults
por: Omosa-Manyonyi, Gloria, et al.
Publicado: (2015) -
Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine
por: Vasan, Sandhya, et al.
Publicado: (2010)